Transparency Market Research
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 – 2018
Buy Now Request Sample
Published Date: Mar 2013
Single User License: US $ 4595 Multi User License: US $ 7595
128 Pages Report
Corporate User License: US $ 10595
REPORT DESCRIPTION Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 – 2018 The Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges
due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body. Likewise, peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses. This report analyzes the peptide therapeutics market by types of applications (cancer, metabolic, neurological diseases and others), route of administration, by types (innovative and generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, and technology. Each of these markets is analyzed by studying the current and future market scenario, with estimation for the period 2010 – 2018 in terms of value in USD million. The peptide therapeutics market is also segmented based on geography into North America, Europe, Asia and rest of the world (RoW) regions. The market for all these geographical regions is provided in the report in terms of revenue. The report provides complete analysis of the factors responsible for driving and restraining the global peptide therapeutics market. Competitive landscape is provided with market players profiled with attributes like company overview,
financial
overview,
business
strategies,
product
portfolio
and
recent
developments. Market shares in 2011 for the key players and CMO players are provided and recommendations to accentuate market shares and ensure sustainability are provided in this report Key market players profiled in this report are Eli Lilly, Roche, Amylin, NovoNordisk, Ipsen and others. While CMOs major players profiled are Bachem, Lonza, Peptisyntha, Polypeptide group and others. Peptide Therapeutics Market, by Applications
Cancer
Metabolic
Cardiovascular
Dermatology
Anti-Infection
Neurology
Gastro Intestinal
Renal
Respiratory
Pain
Others
Peptide Therapeutics Market, by Route of Administration
Parenteral
Oral
Pulmonary
Mucosal
Others
Peptide Therapeutics Market, by Types
Innovative
Generics
Peptide Therapeutics Market, by API Peptide
In-House
CMO (Contract Manufacturing Organization)
Peptide Therapeutics by Technology
Liquid Phase Peptide Synthesis (LPPS)
Solid Phase Peptide Synthesis (SPPS)
Hybrid
Peptide Therapeutics Market, by Geography
North America
Europe
Asia
RoW
Browse full Report with TOC: http://www.transparencymarketresearch.com/peptidetherapeutics-market.html
TABLE OF CONTENTS Chapter 1 Introduction 1.1 Report description 1.2 Market segmentation 1.3 Scope of the report 1.4 Research methodology 1.5 Assumptions
Chapter 2 Executive Summary 2.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million) 2.1.1 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)
2.1.2 Global API peptide therapeutics market, 2011 (USD Million) 2.1.3 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%) Related Reports: Pharmacy Automation Systems Market: http://www.transparencymarketresearch.com/pharmacy-automation-systems.html mHealth Market: http://www.transparencymarketresearch.com/mobile-healthmarket.html
Radiopharmaceuticals Market: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html Insulin Market: http://www.transparencymarketresearch.com/insulin-market.html
Chapter 3 Global Peptide Therapeutics Market Dynamics 3.1 Overview 3.2 Drivers 3.2.1 Increase in cancer patient population to propel the growth of new peptides 3.2.2 Rise in metabolic disorders to escalate the growth of peptides market 3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in coming years 3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011 3.2.4 Technological enhancement has boosted the growth of the market with radical reduction in total production cost of peptides 3.3 Restraints & challenges 3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers 3.3.2 Lack of regulatory standards hampering the growth of the market 3.3.3 Matching equipments with customer requirements is a major challenge for API peptide manufacturers 3.4 Opportunities 3.4.1 Rise in cancer vaccine to drive the future market 3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period
3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore further growth 3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants 3.4.3.2 Major peptide drugs and sales, 2011 (USD Million) 3.5 Porters five forces analysis
3.5.1 Porter’s five forces analysis of global peptide therapeutics market 3.5.2 Bargaining power of suppliers 3.5.3 Bargaining power of buyers 3.5.4 Threat of new entrants 3.5.5 Threat of substitutes 3.5.6 Competitive rivalry 3.6 Market attractiveness analysis 3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography 3.7 Peptide therapeutics - emerging technologies & trends 3.8 Regulatory policies
Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications 4.1 Introduction 4.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million)
4.1.2 Cancer 4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.3 Metabolic 4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.4 Cardiovascular 4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.5 Dermatology 4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012 4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million) 4.1.6 Anti-Infection 4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012 4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million) 4.1.7 Neurology 4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012 4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million) 4.1.8 Gastro Intestinal 4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012 4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)
4.1.9 Renal 4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012 4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million) 4.1.10 Respiratory 4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012 4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million) 4.1.11 Pain 4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012 4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million) 4.1.12 Others 4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012 4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)
Chapter 5 Global Peptide Therapeutics Market, by Route of Administration 5.1 Introduction 5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 2018 (USD Million) 5.1.2 Methods of delivery for peptide drugs 5.2 Parenteral Route 5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million) 5.3 Oral Route 5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million) 5.4 Pulmonary Route 5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million) 5.5 Mucosal Route 5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million) 5.6 Others (Intradermal & Nasal) 5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million) Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments 6.1 Introduction 6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million) 6.2 Peptide Therapeutics – Innovative market 6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)
6.3 Peptide Therapeutics – Generic market 6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)
Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO 7.1 Introduction 7.2 API peptide therapeutics – In-house market 7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)
7.3 Contract Manufacturing Organizations (CMO) 7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)
Chapter 8 Peptide Therapeutics Market, By Technology 8.1 Introduction 8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD Million)
8.2 Solid Phase Peptide Synthesis (SPPS) 8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS) 8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million)
8.4 Hybrid Technology 8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million)
Chapter 9 Peptide Therapeutics Market, By Geography 9.1 Introduction 9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018 9.2 North America 9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million) 9.3 Europe 9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.4 Asia 9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million) 9.5 Rest of World 9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)
Chapter 10 Market Share Analysis 10.1 Market share by key players 10.2 Market share by key players in peptide drugs market 10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%) 10.3 Market share by key players in CMO segment 10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)
Chapter 11 Recommendations 11.1 Success strategies 11.1.1 Rigorous research and development (R&D) initiatives 11.1.2 Investing in emerging economies 11.1.3 Investing in recent technologies such as HPPS TEchnology 11.1.4 Mergers and acquisitions 11.2 Barriers to be considered 11.2.1 The high cost of peptide synthesis 11.2.2 Weak pipeline peptide drug candidates in phase III
Chapter 12 Company Profiles 12.1 Bachem Holding AG 12.1.1 Company overview 12.1.2 Financial overview
12.1.3 Strategic overview 12.1.3.1 Collaborations 12.1.3.2 Expansion 12.1.3.3 Divestiture 12.1.3.4 Recent developments 12.2 Eli Lilly and Company 12.2.1 Company overview 12.2.2 Financial overview 12.2.3 Strategic overview 12.2.3.1 Agreements 12.2.3.2 Approvals 12.2.4 Recent developments 12.3 Pfizer, Inc. 12.3.1 Company overview 12.3.2 Financial overview 12.3.3 Strategic overview 12.3.3.1 Mergers and acquisitions 12.3.3.2 Divestiture 12.3.3.3 Approvals 12.3.4 Recent developments 12.4 Amgen, Inc. 12.4.1 Company overview
12.4.2 Financial overview 12.4.3 Strategic overview 12.4.3.1 Mergers and acquisitions
12.4.3.2 Licensing 12.4.4 Recent developments 12.5 Takeda Pharmaceutical Company Limited 12.5.1 Company overview 12.5.2 Financial overview 12.5.3 Strategic overview 12.5.3.1 Partnerships and collaborations 12.5.3.2 Mergers and acquisitions 12.5.4 Recent developments 12.6 Teva Pharmaceuticals 12.6.1 Company overview 12.6.2 Financial overview 12.6.3 Strategic overview 12.6.3.1 Mergers and acquisitions 12.6.3.2 Investing in generic and biosimilar segments 12.6.4 Recent developments 12.7 Lonza Inc. 12.7.1 Company overview 12.7.2 Financial overview 12.7.3 Strategic overview 12.7.3.1 Investing in emerging economies 12.7.3.2 Mergers and acquisitions 12.7.4 Recent developments 12.8 Peptisyntha 12.8.1 Company overview 12.8.2 Financial overview
12.8.3 Strategic overview 12.8.3.1 Arranging and participating in trade shows 12.8.3.2 Continuous manufacturing expansion 12.9 Sanofi 12.9.1 Company overview 12.9.2 Financial overview 12.9.3 Strategic overview 12.9.3.1 Acquisitions 12.9.3.2 Divestments 12.9.4 Recent developments 12.10 Ipsen 12.10.1 Company overview 12.10.2 Financial overview 12.10.3 Strategic overview 12.10.3.1 Large investment in research and development 12.10.3.2 Global expansion through partnership 12.10.4 Recent developments 12.11 PolyPeptide Group. 12.11.1 Company overview 12.11.2 Strategic overview 12.11.2.1 Focus on product portfolio extension and quality product development
12.11.2.2 Global expansion through merger and acquisition 12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS) 12.12.1 Company overview 12.12.2 Amylin Pharmaceuticals LLC 12.12.3 Financial overview
12.12.4 Strategic overview (Amylin Pharmaceuticals LLC) 12.12.4.1 Entering into strategic collaborations 12.12.4.2 Corporate social responsibility 12.12.4.3 Rigorous R&D initiatives 12.12.5 Recent developments 12.13 AstraZeneca PLC 12.13.1 Company overview 12.13.2 Financial overview 12.13.3 Strategic overview 12.13.3.1 Rigorous R&D initiatives 12.13.3.2 Investing in emerging economies 12.13.4 Recent developments 12.14 Roche 12.14.1 Company overview 12.14.2 Financial overview 12.14.3 Strategic overview 12.14.3.1 Research and development initiatives 12.14.3.2 Focus on personalized healthcare 12.14.3.3 Focus on new and emerging markets 12.14.3.4 Funding awareness programs 12.14.4 Recent developments 12.15 GlaxoSmithKline (GSK) 12.15.1 Company overview 12.15.2 Financial overview 12.15.3 Strategic overview 12.15.3.1 Research and development initiatives
12.15.3.2 Direct to Consumer Advertising 12.15.3.3 Mergers and acquisitions 12.15.4 Recent developments 12.16 Merck & Co. 12.16.1 Company overview 12.16.2 Financial overview 12.16.3 Strategic overview 12.16.3.1 Corporate social responsibility 12.16.3.2 R&D Initiatives 12.16.3.3 Strategic alliances and out-licensing 12.16.4 Recent developments 12.17 Novartis AG 12.17.1 Company overview 12.17.2 Financial overview 12.17.3 Strategic overview 12.17.3.1 Mergers and acquisitions 12.17.3.2 Memorandum of understanding 12.17.4 Recent developments 12.18 Novo-Nordisk A/S 12.18.1 Company overview 12.18.2 Financial overview 12.18.3 Strategic overview 12.18.3.1 Partnerships and alliances 12.18.4 Agreements 12.18.5 Recent developments
About Us: Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Blogs: http://usamarketresearch.wordpress.com/ http://usamarketresearch.blogspot.com/ Browse full Report with TOC: http://www.transparencymarketresearch.com/peptidetherapeutics-market.html